123 related articles for article (PubMed ID: 22392361)
1. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping.
Schwartz GF; Reis-Fihlo J; Pusztai L; Fentiman IS; Holland R; Bartelink H; Rutgers EJ; Solin LJ; Palazzo J;
Cancer; 2012 Apr; 118(8):2031-8. PubMed ID: 22392361
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
3. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping.
Schwartz GF; Bartelink H; Burstein HJ; Cady B; Cataliotti L; Fentiman IS; Holland R; Hughes KS; Masood S; McCormick B; Palazzo JA; Pressman PI; Reis-Filho J; Pusztai L; Rutgers EJ; Seidman AD; Solin LJ; Sparano JA
Breast J; 2012; 18(4):303-11. PubMed ID: 22759093
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm.
Russell CA
Curr Womens Health Rep; 2002 Apr; 2(2):134-9. PubMed ID: 12116603
[TBL] [Abstract][Full Text] [Related]
6. [Early-stage breast cancer - strategies for adjuvant systemic therapy].
Görner M; Just M; Gerull S
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):230-8. PubMed ID: 18716990
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
9. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
10. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
11. Role of chemotherapy in breast cancer.
Hussain SA; Palmer DH; Stevens A; Spooner D; Poole CJ; Rea DW
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1095-110. PubMed ID: 16336100
[TBL] [Abstract][Full Text] [Related]
12. The influence of a gene expression profile on breast cancer decisions.
Henry LR; Stojadinovic A; Swain SM; Prindiville S; Cordes R; Soballe PW
J Surg Oncol; 2009 May; 99(6):319-23. PubMed ID: 19204954
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy in primary carcinoma of the breast].
Harbeck N
Zentralbl Gynakol; 2003 Sep; 125(9):322-6. PubMed ID: 14569511
[TBL] [Abstract][Full Text] [Related]
14. Meeting highlights--International Consensus Panel on the treatment of primary breast cancer.
Taguchi T
Gan To Kagaku Ryoho; 2002 Mar; 29(3):347-63. PubMed ID: 11915723
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
Andre F; Pusztai L
Nat Clin Pract Oncol; 2006 Nov; 3(11):621-32. PubMed ID: 17080180
[TBL] [Abstract][Full Text] [Related]
16. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
Montemurro F; Aglietta M
Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
[TBL] [Abstract][Full Text] [Related]
18. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
19. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.
Benchalal M; Le Prisé E; de Lafontan B; Berton-Rigaud D; Belkacemi Y; Romestaing P; Peignaux K; Courdi A; Monnier A; Montcuquet P; Goudier MJ; Marchal C; Chollet P; Abadie-Lacourtoisie S; Datchary J; Veyret C; Kerbrat P
Cancer; 2005 Jul; 104(2):240-50. PubMed ID: 15948160
[TBL] [Abstract][Full Text] [Related]
20. Variations in the treatment of early-stage breast cancer in Quebec between 1988 and 1994.
Hébert-Croteau N; Brisson J; Latreille J; Blanchette C; Deschênes L
CMAJ; 1999 Oct; 161(8):951-5. PubMed ID: 10551190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
